| Literature DB >> 24846412 |
Anders A Tveita1, Fredrik H Schjesvold, Olav Sundnes, Ole Audun W Haabeth, Guttorm Haraldsen, Bjarne Bogen.
Abstract
Tumor-specific Th1 cells can activate tumor-infiltrating macrophages that eliminate MHC class II negative (MHC II(NEG)) tumor cells. Activated M1-like macrophages lack antigen (Ag) receptors, and are presumably unable to discriminate and thus kill both Ag-positive (Ag(POS)) and Ag-negative (Ag(NEG)) tumor cells (bystander killing). The lack of specificity of macrophage-mediated cytotoxicity might be of clinical importance as it could provide a means of avoiding tumor escape. Here, we have tested this idea using mixed populations of Ag(POS) and Ag(NEG) tumor cells in a TCR-transgenic model in which CD4(+) T cells recognize a secreted tumor-specific antigen. Surprisingly, while Ag(POS) tumor cells were recognized and rejected, Ag(NEG) cells grew unimpeded and formed tumors. We further demonstrated that macrophage-mediated cytotoxicity was spatially restricted to areas dominated by Ag(POS) tumor cells, sparing Ag(NEG) tumor cells in the vicinity. As a consequence, macrophage tumoricidal activity did not confer bystander killing in vivo. The present results offer novel insight into the mechanisms of indirect Th1-mediated elimination of MHC II(NEG) tumor cells.Entities:
Keywords: Bystander killing; CD4+ T-cell immunotherapy; Macrophage cytotoxicity; Macrophage polarization; Myeloma
Mesh:
Substances:
Year: 2014 PMID: 24846412 DOI: 10.1002/eji.201444659
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532